TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates are Ublituximab IV (anti-CD20 mAb), Ublituximab Subcutaneous (anti-CD20 mAb), Azer-cel, TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition, and/or investment opportunities.
企業コードTGTX
会社名TG Therapeutics Inc
上場日Dec 14, 1995
最高経営責任者「CEO」Weiss (Michael S)
従業員数338
証券種類Ordinary Share
決算期末Dec 14
本社所在地3020 Carrington Mill Blvd., Suite 475
都市MORRISVILLE
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号27560-5435
電話番号18775758489
ウェブサイトhttps://www.tgtherapeutics.com/
企業コードTGTX
上場日Dec 14, 1995
最高経営責任者「CEO」Weiss (Michael S)
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし